Table 3.
Examples of studies in patients with MF that require or allow previous exposure to ruxolitinib (adapted from [83])
| Drug class | Drug | Mechanism of action | Clinical development phase | ClinicalTrials.gov number |
|---|---|---|---|---|
| JAK inhibitors | Itacitinib (± ruxolitinib) | JAK1 inhibitor | 2 | NCT03144687 |
| NS-018 | JAK2 inhibitor | 1/2 | NCT01423851 | |
| LY2784544 | JAK2 inhibitor | 2 | NCT01594723 | |
| Epigenetic modifiers | Pracinostat + ruxolitinib | HDAC inhibitor | 2 | NCT02267278 |
| Panobinostat + ruxolitinib | HDAC inhibitor | 1 | NCT01693601 | |
| Azacitidine + ruxolitinib | HMA | 2 | NCT01787487 | |
| SGI-110 | HMA | 2 | NCT03075826 | |
| IMG-7289 | LSD1 inhibitor | 2 | NCT03136185 | |
| PI3K/AKT/mTOR pathway inhibitors | Parsaclisib + ruxolitinib | PI3K inhibitor | 2 | NCT02718300 |
| Buparlisib | PI3K inhibitor | 1 | NCT01730248 | |
| TGR-1202 + ruxolitinib | PI3Kδ inhibitor | 1 | NCT02493530 | |
| Small molecule inhibitors | CPI-0610 (± ruxolitinib) | BET inhibitor | 1/2 | NCT02158858 |
| PIM447 + ruxolitinib | Pan-PIM kinase inhibitor | 1 | NCT02370706 | |
| Ribociclib + ruxolitinib | CDK4/6 | 1 | NCT02370706 | |
| Navitoclax (± ruxolitinib) | BCL-2 inhibitor | 2 | NCT03222609 | |
| Alisertib | Aurora kinase A | Not applicable | NCT02530619 | |
| Checkpoint inhibitors | Pembrolizumab | PD-1 inhibitor | 2 | NCT03065400 |
| Nivolumab | PD-1 inhibitor | 2 | NCT02421354 | |
| Novel agents | Imetelstat | Telomerase inhibitor | 2 | NCT02426086 |
| Glasdegib | Hedgehog inhibitor | 2 | NCT02226172 | |
| PRM-151 | Pentraxin 2 agonist | 2 | NCT01981850 | |
| Sotatercept | TGF-β ligand trap | 2 | NCT01712308 | |
| P1101 | Peg-interferon-α | 2 | NCT02370329 | |
| LCL-161 | Mitochondrial-derived activator of caspases (SMAC) mimetic | 2 | NCT02098161 |
BCL-2 B-cell lymphoma 2, BET bromodomain and extraterminal domain, HDAC histone deacetylase, HMA hypomethylating agent, JAK, Janus kinase, LSD1 lysine-specific demethylase 1, mTOR mammalian target of rapamycin, PI3K phosphoinositide 3-kinase, PD-1 programmed cell death protein 1, TGF-β transforming growth factor beta